These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 22005114)

  • 41. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Radionuclide therapy for neuroendocrine tumours].
    Mortensen J; Oturai P; Højgaard L; Knigge U; Hansen CP; Martiný L; Rasmussen P; Kjaer A
    Ugeskr Laeger; 2010 Oct; 172(43):2950-3. PubMed ID: 21040673
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
    Taïeb D; Garrigue P; Bardiès M; Abdullah AE; Pacak K
    PET Clin; 2015 Oct; 10(4):477-86. PubMed ID: 26384594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Gastroenteropancreatic neuroendocrine tumors: diagnosis and therapy in nuclear medicine].
    Haug AR; Bartenstein P
    Internist (Berl); 2012 Feb; 53(2):161-6. PubMed ID: 22231696
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nuclear imaging of neuroendocrine tumours.
    Sundin A; Garske U; Orlefors H
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Das S; Al-Toubah T; El-Haddad G; Strosberg J
    Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1023-1031. PubMed ID: 31652074
    [No Abstract]   [Full Text] [Related]  

  • 48. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
    Parus JL; Mikolajczak R
    Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
    Kaltsas GA; Mukherjee JJ; Grossman AB
    Ann Oncol; 2001; 12 Suppl 2():S47-50. PubMed ID: 11762352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.
    Bodei L; Kwekkeboom DJ; Kidd M; Modlin IM; Krenning EP
    Semin Nucl Med; 2016 May; 46(3):225-38. PubMed ID: 27067503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.
    Nisa L; Savelli G; Giubbini R
    Ann Nucl Med; 2011 Feb; 25(2):75-85. PubMed ID: 21107762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.
    Breeman WA; Mearadji A; Capello A; Bernard BF; van Eijck CH; Krenning EP; de Jong M
    Int J Cancer; 2003 Apr; 104(3):376-9. PubMed ID: 12569562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
    Mure A; Lebtahi R; de Labriolle-Vaylet C; Askienazy S
    Gastroenterol Clin Biol; 1998 Oct; 22(10):809-18. PubMed ID: 9854206
    [No Abstract]   [Full Text] [Related]  

  • 56. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.
    Bombardieri E; Coliva A; Maccauro M; Seregni E; Orunesu E; Chiti A; Lucignani G
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):3-15. PubMed ID: 20168282
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
    Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
    Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP
    Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
    Chiti A; Spinelli A; Bombardieri E
    Radiol Med; 1997 Oct; 94(4):362-70. PubMed ID: 9465244
    [No Abstract]   [Full Text] [Related]  

  • 60. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
    Kwekkeboom DJ; Krenning EP
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.